Synedgen

GlycoMira Therapeutics is a preclinical-stage biopharmaceutical company developing a new class of innate immune system modulators based on polysaccharides that naturally occur within the body. GlycoMira’s dedicated team is working tirelessly toward a vision that will transform the way cancer and other inflammatory diseases are treated. Preclinical development of GlycoMira’s lead drug candidate — GM-1111 — has demonstrated that GM-1111 has tremendous potential to address unmet needs in solid tumor treatment and supportive care.

REGENTYS™ is a development stage, regenerative medicine company focused on developing treatments for patients with gastrointestinal (GI) disorders. Generex Biotechnology Partner Regentys Corporation Receives European Patent Approval for ECMH™ for Treatment of Ulcerative Colitis. We are a development stage regenerative medicine company whose mission is to develop novel applications of extracellular matrix to treat IBD and put patients suffering with the disease into deep remission. Our first product, ExtraCellular Matrix Hydrogel (ECMH), is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis. The McGowan Institute is the most ambitious regenerative program in the nation, coupling biology, clinical science and engineering. To provide patients suffering with IBD, and other diseases of the lower GI and urogenital tract, regenerative medicine treatments for their disease, to improve their quality of life.

Mesentech is developing innovative drugs that can selectively distribute to musculoskeletal tissue. Mesentech has developed novel chemistry that selectively delivers pharmaceuticals to a specific tissue. Robert Young, who led teams that discovered SingulAir, Vioxx, Arcoxia, ondanacatib, among others while leading medicinal chemistry at Merck. MES1022 is a clinical stage compound that regenerates muscle and bone with selective distribution to to musculoskeletal system. Our first clinical program utilizes tissue-selective distribution to deliver prostaglandin, a potent hormone that triggers the body's own regenerative process, to musculoskeletal tissue to renew and repair muscle and bone.

Our goal is to create long-term and mutually respectful and beneficial relationships with all levels of those in the medical/bio-pharma research field. We are also developing a pioneering delivery matrix which is designed to provide gastro-protection to deliver enzymes and other compounds, that are designed to work in the GI tract beyond the stomach, to the site of action in the small intestines. We focus on bioactive substances, and actively explore opportunities where we have identified large market potentials, coupled with unmet patient needs, and we can identify and harness innovative solutions. With a specific emphasis on preserving the microbiome , we developed an iron-based nano-particulate compound to address the effects caused by iron deficiency as well as the currently available therapeutic solutions. E40 is a new Glutenase, developed to specifically address these conditions. We operate a diversified, independent platform with multi-product capabilities. In the short term we take products through the novel food supplement or medical device route, but with a longer term plan to take these compounds to drug status and to be phase II, ready to out-license products for drug development for the prescriptions market. In order to do this all our pre-clinical, clinical and manufacturing development activities are carried out, through any development stage, in GLP and GMP standard.

Since 2021 Gnubiotics has been developing a next generation of immunotherapy and now seeks to progress its lead candidate, GNU101, a promising glycopeptide therapeutic to the next step of IND approval and phase 1 trials. Gnubiotics Sciences SA is partnering with top-tier academic medical centers to move into first clinical trials. We are impacting 4 areas of high unmet needthrough the GENESIS platform:. The glycopeptides developed by Gnubiotics have been demonstrated to intelligently promote microbiome balance by specifically promoting the growth of beneficial bacteria. Glyopeptide variants developed by Gnubiotics have been demonstrated to reduce the onset of diet induced obesity and enhance thermogenesis through a number of hypothesized mechanisms of action. Gnubiotics is interested in further investigating this promising MoAs through partnerships and collaborations. Prior to co-founding Gnubiotics, Bernardo worked as an investment banker and had an impact as a consultant. We have mastered the intelligent, rational design and manufacturing of precise complex glycopeptide biologics that target and affect these biological systems.

We are a clinical stage private company focused on developing therapies for infectious, inflammatory and degenerative diseases. We are led by a team of seasoned pharmaceutical executives with extensive operational, scientific and financial experience in life sciences. We are a clinical stage private company focused on developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin (pGSN). Plasma Gelsolin (“pGSN”) is a master regulator of the immune system. It is a unique anti-inflammatory without immunosuppressive properties. Building upon IP and know-how licensed from Harvard Medical School, we are developing a portfolio of products based on repletion of the highly conserved, abundant human protein plasma gelsolin. The first product is in Phase 2 and follow on products are in development. Rhu-pGSN is a non-antibiotic, host-directed, non-immunosuppressive treatment for inflammation due to both infectious and non-infectious causes.